133 related articles for article (PubMed ID: 31481171)
1. Disclosure of amyloid PET scan results: A systematic review.
Kim H; Lingler JH
Prog Mol Biol Transl Sci; 2019; 165():401-414. PubMed ID: 31481171
[TBL] [Abstract][Full Text] [Related]
2. Disclosure of amyloid positron emission tomography results to individuals without dementia: a systematic review.
de Wilde A; van Buchem MM; Otten RHJ; Bouwman F; Stephens A; Barkhof F; Scheltens P; van der Flier WM
Alzheimers Res Ther; 2018 Jul; 10(1):72. PubMed ID: 30055660
[TBL] [Abstract][Full Text] [Related]
3. Cognitively unimpaired adults' reactions to disclosure of amyloid PET scan results.
Largent EA; Harkins K; van Dyck CH; Hachey S; Sankar P; Karlawish J
PLoS One; 2020; 15(2):e0229137. PubMed ID: 32053667
[TBL] [Abstract][Full Text] [Related]
4. Safety of disclosing amyloid status in cognitively normal older adults.
Burns JM; Johnson DK; Liebmann EP; Bothwell RJ; Morris JK; Vidoni ED
Alzheimers Dement; 2017 Sep; 13(9):1024-1030. PubMed ID: 28263740
[TBL] [Abstract][Full Text] [Related]
5. Psychological, behavioral and social effects of disclosing Alzheimer's disease biomarkers to research participants: a systematic review.
Bemelmans SA; Tromp K; Bunnik EM; Milne RJ; Badger S; Brayne C; Schermer MH; Richard E
Alzheimers Res Ther; 2016 Nov; 8(1):46. PubMed ID: 27832826
[TBL] [Abstract][Full Text] [Related]
6. A randomized controlled trial of amyloid positron emission tomography results disclosure in mild cognitive impairment.
Lingler JH; Sereika SM; Butters MA; Cohen AD; Klunk WE; Knox ML; McDade E; Nadkarni NK; Roberts JS; Tamres LK; Lopez OL
Alzheimers Dement; 2020 Sep; 16(9):1330-1337. PubMed ID: 32588971
[TBL] [Abstract][Full Text] [Related]
7. "And Does That Necessarily Mean Absolutely Alzheimer's?" An Analysis of Questions Raised Following Amyloid PET Results Disclosure.
Kim JE; Tamres LK; Orbell SL; Cheng RZ; Klunk WE; Aizenstein HJ; Butters MA; McDade E; Lingler JH
Am J Geriatr Psychiatry; 2024 Jan; 32(1):45-54. PubMed ID: 37634955
[TBL] [Abstract][Full Text] [Related]
8. Amnestic MCI patients' experiences after disclosure of their amyloid PET result in a research context.
Vanderschaeghe G; Schaeverbeke J; Bruffaerts R; Vandenberghe R; Dierickx K
Alzheimers Res Ther; 2017 Dec; 9(1):92. PubMed ID: 29197423
[TBL] [Abstract][Full Text] [Related]
9. Disclosure of positron emission tomography amyloid imaging results: A preliminary study of safety and tolerability.
Lim YY; Maruff P; Getter C; Snyder PJ
Alzheimers Dement; 2016 Apr; 12(4):454-8. PubMed ID: 26750717
[TBL] [Abstract][Full Text] [Related]
10. Disclosure of preclinical Alzheimer's disease biomarker results in research and clinical settings: Why, how, and what we still need to know.
Erickson CM; Chin NA; Johnson SC; Gleason CE; Clark LR
Alzheimers Dement (Amst); 2021; 13(1):e12150. PubMed ID: 33665341
[TBL] [Abstract][Full Text] [Related]
11. A Pragmatic, Investigator-Driven Process for Disclosure of Amyloid PET Scan Results to ADNI-4 Research Participants.
Erickson CM; Karlawish J; Grill JD; Harkins K; Landau SM; Rivera-Mindt MG; Okonkwo O; Petersen RC; Aisen PS; Weiner MW; Largent EA
J Prev Alzheimers Dis; 2024; 11(2):294-302. PubMed ID: 38374735
[TBL] [Abstract][Full Text] [Related]
12. Development of a Standardized Approach to Disclosing Amyloid Imaging Research Results in Mild Cognitive Impairment.
Lingler JH; Butters MA; Gentry AL; Hu L; Hunsaker AE; Klunk WE; Mattos MK; Parker LS; Roberts JS; Schulz R
J Alzheimers Dis; 2016 Mar; 52(1):17-24. PubMed ID: 27060950
[TBL] [Abstract][Full Text] [Related]
13. Stakeholders' Views on Early Diagnosis for Alzheimer's Disease, Clinical Trial Participation and Amyloid PET Disclosure: A Focus Group Study.
Vanderschaeghe G; Vandenberghe R; Dierickx K
J Bioeth Inq; 2019 Mar; 16(1):45-59. PubMed ID: 30868358
[TBL] [Abstract][Full Text] [Related]
14. From information to follow-up: Ethical recommendations to facilitate the disclosure of amyloid PET scan results in a research setting.
Vanderschaeghe G; Schaeverbeke J; Bruffaerts R; Vandenberghe R; Dierickx K
Alzheimers Dement (N Y); 2018; 4():243-251. PubMed ID: 29955667
[TBL] [Abstract][Full Text] [Related]
15. Testing and disclosures related to amyloid imaging and Alzheimer's disease: Common questions and fact sheet summary.
Rabinovici GD; Karlawish J; Knopman D; Snyder HM; Sperling R; Carrillo MC
Alzheimers Dement; 2016 Apr; 12(4):510-5. PubMed ID: 27103054
[TBL] [Abstract][Full Text] [Related]
16. Comprehension of an Elevated Amyloid Positron Emission Tomography Biomarker Result by Cognitively Normal Older Adults.
Mozersky J; Sankar P; Harkins K; Hachey S; Karlawish J
JAMA Neurol; 2018 Jan; 75(1):44-50. PubMed ID: 29059270
[TBL] [Abstract][Full Text] [Related]
17. The psychological impact of disclosing amyloid status to Japanese elderly: a preliminary study on asymptomatic patients with subjective cognitive decline.
Wake T; Tabuchi H; Funaki K; Ito D; Yamagata B; Yoshizaki T; Kameyama M; Nakahara T; Murakami K; Jinzaki M; Mimura M
Int Psychogeriatr; 2018 May; 30(5):635-639. PubMed ID: 29094656
[TBL] [Abstract][Full Text] [Related]
18. Should we disclose amyloid imaging results to cognitively normal individuals?
Grill JD; Johnson DK; Burns JM
Neurodegener Dis Manag; 2013 Feb; 3(1):43-51. PubMed ID: 25285157
[TBL] [Abstract][Full Text] [Related]
19. Development of a process to disclose amyloid imaging results to cognitively normal older adult research participants.
Harkins K; Sankar P; Sperling R; Grill JD; Green RC; Johnson KA; Healy M; Karlawish J
Alzheimers Res Ther; 2015; 7(1):26. PubMed ID: 25969699
[TBL] [Abstract][Full Text] [Related]
20. Amyloid positron emission tomography in sporadic cerebral amyloid angiopathy: A systematic critical update.
Farid K; Charidimou A; Baron JC
Neuroimage Clin; 2017; 15():247-263. PubMed ID: 28560150
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
